Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  Biotech
Latest

Amgen’s new drug could be a blockbuster

By   /  Friday, June 4th, 2021  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, right, Subscriber content, Technology, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen’s new drug could be a blockbuster

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen reaches billion-dollar licensing deal with Japanese firm

By   /  Wednesday, June 2nd, 2021  /  Banking & Finance, Biotech, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen reaches billion-dollar licensing deal with Japanese firm

Amgen announced an agreement June 1 with Kyowa Kirin, a Japanese pharmaceutical company, to jointly develop and commercialize a human monoclonal antibody that Kyowa Kirin is developing to treat atopic dermatitis and other autoimmune diseases. The deal could be worth $1.25 billion or more. Amgen will led the development, manufacturing and commercialization for the treatment, Read More →

Read More →
Latest

Amgen gets FDA approval for potential billion-dollar drug

By   /  Friday, May 28th, 2021  /  Banking & Finance, Biotech, East Ventura County, Latest news, right, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen gets FDA approval for potential billion-dollar drug

Thousand Oaks-based Amgen won approval from the U.S. Food and Drug Administration on May 28 for its latest oral drug treatment, Lumakras, potentially adding another huge market for one of the largest biotech firms in the world. According to the Wall Street Journal, Amgen will charge $17,900 a month for the drug and analyst think Read More →

Read More →
Latest

Revenue up at MannKind, but losses mount

By   /  Wednesday, May 12th, 2021  /  Banking & Finance, Biotech, Central Coast Health Watch, Earnings, East Ventura County, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Revenue up at MannKind, but losses mount

Westlake Village-based biotech company MannKind saw a slight bump in revenue in the first quarter thanks to its product Afrezza, but net losses continued to climb. MannKind released its earnings after the markets closed on May 12. It ended the day down 8.6% and regained 0.25% on May 13, to close at $4.03. MannKind, which Read More →

Read More →
Latest

Westlake Village BioPartners makes big bet on gene therapy with Capsida

By   /  Friday, May 7th, 2021  /  Biotech, East Ventura County, Latest news, Subscriber content, Technology, Top Stories, Tri-County Economy  /  Comments Off on Westlake Village BioPartners makes big bet on gene therapy with Capsida

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen planning apartments on its land in Thousand Oaks

By   /  Friday, May 7th, 2021  /  Biotech, East Ventura County, Latest news, Real Estate, Subscriber content, Top Stories, Tri-County Economy  /  Comments Off on Amgen planning apartments on its land in Thousand Oaks

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Arcutis shares down after earnings report

By   /  Tuesday, May 4th, 2021  /  Banking & Finance, Biotech, Earnings, East Ventura County, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Arcutis shares down after earnings report

Westlake Village-based Arcutis Biotherapeutics suffered a net loss in the first quarter of fiscal year 2021, but continues to hold a strong financial position with $446.5 million in assets. According to earnings released May 4, Arcutis lost $36 million in the first quarter, or 76 cents per share, compared to a loss of $28 million, Read More →

Read More →